Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy

Stanković, Žana; Ille, Tatjana

doi:10.2298/vsp1303267s

Cited by 7 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, there is little data on the application of the MARS on patients receiving LAA. One study showed a positive correlation between receiving long acting fluphenazine and the MARS score [17] which agrees with our findings.…”

Section: Discussionsupporting

confidence: 93%

Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics

Dur¹,

Harvey²,

Cáceda³

2017

Neuropsychiatry

View full text Add to dashboard Cite

Introduction:Clozapine is a cornerstone in the treatment of resistance schizophrenia, whereas long-acting antipsychotics (LAA) are central in the care of patients with poor compliance. Both populations represent daunting challenges. We aim to compare pre-treatment disease severity and treatment outcome of patients receiving clozapine and LAA. Methods:Medical records of patients who attend an outpatient schizophrenia clinic were randomized and examined retrospectively. Demographics and psychiatric history prior hospitalizations and suicide attempts were reviewed. Additionally, the Positive and Negative Symptom Scale (PANSS) and Medication Adherence Rating Scale (MARS) were administered to patients during their last visit. Results:Preliminary results from 27 patients show that those on LAA had more hospitalizations (p=0.021) and suicide attempts (75% vs. 11%, p=0.034) than patients on clozapine before initiation of treatment. There were no differences in frequency of visits, MARS or PANSS scores between the two groups. Negative symptoms were more predominant among the patients on long-acting antipsychotics than in those on clozapine, although the difference was borderline significant. Discussion:Patients on LAA had a more severe disease course prior to the initiation of LAA, reflected in more hospitalizations and suicide attempts, possibly due to persistent non-compliance with oral treatment in the past. Patients on clozapine had more recent hospitalizations, perhaps due to suboptimal dosing. Treatment adherence and symptom burden were similar in both patient groups. There was an expected trend of patients on long acting antipsychotics to display poorer negative symptom control than those on clozapine.

show abstract

Section: Discussionsupporting

confidence: 93%

Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics

Dur¹,

Harvey²,

Cáceda³

2017

Neuropsychiatry

View full text Add to dashboard Cite

show abstract

“…2017a, 2017b, 2017c; Remington & Khramov 2001; Song et al . 2019; Stanković & Ille 2013; Taipale et al . 2018; Tiihonen et al .…”

Section: Resultsmentioning

confidence: 99%

“…The true effect in 95% of all comparable populations fell within the prediction interval 0.16-23.50 (see supplemental materials). Furthermore, three studies (Joshi et al 2018b;Rosenheck et al 2011;Stankovi c & Ille 2013) found no differences in mean scores on the DAI (n = 1075, 95% CI = À0.399 to 2.731, P = 0.144; s 2 = 1.876, I 2 = 98.89%, Q = 180.473, df = 2, P < 0.001).…”

Section: Medication Adherencementioning

confidence: 95%

The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis

Okoli

Kappi

Wang

et al. 2021

Int J Mental Health Nurs

View full text Add to dashboard Cite

Long-acting injectable (LAI) antipsychotic medications may be an important modality of reducing costs, improving symptoms, and fostering quality of life outcomes for those with schizophrenia. Our objective was to systematically review and conduct a meta-analysis of the effectiveness of LAIs compared with oral antipsychotics on medication adherence, symptom remission/relapse, rehospitalization, outpatient visits, emergency department visits, healthcare costs, and social functioning. We performed a systematic search of PsycInfo, CINAHL, PubMed, and Scopus databases to examine studies meeting inclusion criteria prior to August 30th, 2020. Randomized controlled trials, retrospective studies, prospective studies among people with schizophrenia with at least 6-month follow-up data were obtained. Overall effect sizes and associated 95% confidence intervals (CI) were estimated with random-effects modeling. We found 75 articles meeting our inclusion criteria, including 341 730 individuals with schizophrenia. Systematic review results indicated that LAIs compared with orals improved medication adherence (25/29 studies), symptom remission/relapse (10/18 studies), rehospitalizations (26/49 studies), emergency department visits (9/17 studies), medical costs (11/15 studies), and social functioning (5/9 studies); however, LAIs also increased outpatient visits (7/16 studies) and pharmacy costs (10/10 studies). Meta-analytic results of studies with similar outcome measures did not find differences between LAIs and orals in respect to outcomes, except lowering emergency department visits and increasing pharmacy costs. The differences between the results of the

show abstract

“…Long-acting antipsychotics 19,24 Clients on long-acting depot injections may have a more favorable medication attitude and outcome.…”

Section: Non-therapy-based Strategiesmentioning

confidence: 99%

A Case Review of Poor Insight in Schizophrenia: How Much Do We Know?

Bastiaens¹,

Agarkar²

2014

Psychiatric Annals

View full text Add to dashboard Cite

Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy

Abstract: Schizophrenic patients on classical depot antipsychotic maintenance therapy might present subpopulation of patients with significantly longer illness duration, more favorable medication attitude and outcome in relation to those on oral antipsychotics alone.

Cited by 7 publications

References 29 publications

Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics

Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics

The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis

A Case Review of Poor Insight in Schizophrenia: How Much Do We Know?

Contact Info

Product

Resources

About